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The unprecedented emergence in Asia of multiple avian influenza virus (AIV) subtypes with a
broad host range poses a major challenge in the design of vaccination strategies that are both
effective and available in a timely manner. The present study focused on the protective effects of a
genetically modified AIV as a source for the preparation of vaccines for epidemic and pandemic
influenza. It has previously been demonstrated that a live attenuated AIV based on the internal
backbone of influenza A/Guinea fowl/Hong Kong/WF10/99 (H9N2), called WF10att, is effective
at protecting poultry species against low- and high-pathogenicity influenza strains. More
importantly, this live attenuated virus provided effective protection when administered in ovo.I n
order to characterize the WF10att backbone further for use in epidemic and pandemic influenza
vaccines, this study evaluated its protective effects in mice. Intranasal inoculation of modified
attenuated viruses in mice provided adequate protective immunity against homologous lethal
challenges with both the wild-type influenza A/WSN/33 (H1N1) and A/Vietnam/1203/04 (H5N1)
viruses. Adequate heterotypic immunity was also observed in mice vaccinated with modified
attenuated viruses carrying H7N2 surface proteins. The results presented in this report suggest
that the internal genes of a genetically modified AIV confer similar protection in a mouse model
and thus could be used as a master donor strain for the generation of live attenuated vaccines for
epidemic and pandemic influenza.
INTRODUCTION
In the 20th century, humans experienced three pandemics
of influenza with significant death tolls (Horimoto &
Kawaoka, 2001). The emergence of highly pathogenic
H5N1 avian influenza virus (AIV) in Asia, with an
unusually broad host range and the ability to infect and
kill people, has raised concerns that another pandemic is
looming over us (Horimoto & Kawaoka, 2001). Vaccines
are undoubtedly a major resource that can greatly reduce
the impact of the pandemic. Currently, two types of
vaccine are commercially available for the prevention of
epidemic influenza in the USA: inactivated whole virion
and live attenuated vaccines (Belshe, 2004; Harper et al.,
2004; Zangwill & Belshe, 2004). FluMist is a live attenuated
influenza vaccine composed of the three dominant
circulating strains of human influenza virus types A and
B. This vaccine has been shown to be efficacious and safe
for delivery in children and adults aged 5–49 and is not
transmissible to susceptible contacts (Belshe, 2004; Harper
et al., 2004). The two type A influenza viruses present
within the FluMist vaccine are reassortants containing the
surface genes of the currently circulating H1N1 and H3N2
strains and six internal genes from the master donor virus
influenza A/Ann Arbor/6/60 (H2N2) (MDV-A) with a
cold-adapted (ca), temperature-sensitive (ts) and attenu-
ated (att) phenotype (Maassab, 1967).
Murphy et al. (1982, 1997) and Subbarao et al. (1995)
developed alternative approaches for the generation of live
attenuated vaccines for humans using reassortants between
avian and human influenza A viruses. The main concept
behind these latter approaches was based on the host-range
restriction shown by AIVs. Thus, viruses carrying genes
derived from an AIV would be attenuated in humans,
whereas the presence of the human haemagglutinin (HA)
and neuraminidase (NA) surface proteins would elicit a
protective immune response against circulating influenza A
viruses. These experimental vaccines showed great promise
in pre-clinical studies and in clinical studies in adults and
older children (Sears et al., 1988; Steinhoff et al., 1990).
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young children and infants, resulting in high fever and
other flu-like symptoms. In addition, the consistent failure
to obtain some of the reassortant viruses made these
approaches impractical (Steinhoff et al., 1990, 1991).
The advent of reverse genetics has opened up new
alternatives for the development of live attenuated vaccines
(Neumann & Kawaoka, 2001).This isparticularlyimportant
considering the unprecedented emergence of multiple
strains of AIVs with unexpectedly broad host ranges
(Capua & Marangon, 2004). If one of these strains was
spread among a broad range of animal species, we should
expect major health, economic and ecological consequences.
It is unrealistic to consider the preparation of multiple
vaccine formulations specifically tailored for multiple
animal species if such a strain were to emerge (Capua &
Alexander, 2002, 2004; Capua & Marangon, 2004). We have
previously analysed an AIV backbone that has shown a
broad host range, influenza A/Guinea fowl/Hong Kong/
WF10/99 (H9N2) (WF10), for its potential as a suitable
virus vaccine donor that could be used in multiple animal
species, including humans (Song et al., 2007). H9N2 viruses
of the same lineage as the WF10 virus have been shown to
effectively infect multiple domestic poultry species, includ-
ing ducks, turkeys, chickens and quail, as well as mice,
without prior adaptation (Choi et al., 2004; Guan et al.,
2000; Lin et al., 2000; Peiris et al., 1999, 2001; Perez et al.,
2003a, b; Xu et al., 2004). Viruses phylogenetically related to
the WF10 virus have also been isolated from pigs (Xu et al.,
2004). Furthermore, we have shown that the WF10 virus has
many biological features similar to human influenza viruses,
including the ability to infect non-ciliated cells in cultures of
human airway epithelial cells (Wan & Perez, 2007). Thus,
WF10 represents a potentially ideal candidate for the
preparation of live vaccines applicable to multiple animal
species. In previous studies, we showed that introduction of
the MDV-A mutations into the WF10 virus in combination
with an epitope HA tag in frame with the C terminus of the
PB1 polymerase subunit resulted in a virus with an att
phenotype and provided excellent protection in birds (Song
et al., 2007). In this study, we wanted to expand on the
characterization of the genetically modified WF10 backbone
as a vaccine donor for influenza viruses of other animal
species. Our results showed that genetically modified WF10
reassortant viruses induced protective immunity against the
highly lethal influenza A/WSN/33 (H1N1) and A/Vietnam/
1203/04 (H5N1) strains in mice. Furthermore, vaccination
with a heterologous subtype also resulted in adequate cross-
protection. These studies highlight the potential of a
genetically modified AIV backbone as a donor for influenza
vaccines for avian and mammalian species.
METHODS
Cells and viruses. 293T human embryonic kidney and Madin–
Darby canine kidney (MDCK) cells were maintained as described by
Song et al. (2007). The WF10 and the mouse-adapted influenza A/
WSN/33 (H1N1) (WSN) viruses were kindly provided by Dr Robert
Webster, St Jude Children’s Research Hospital, Memphis, TN, USA.
The highly pathogenic AIV A/Vietnam/1203/04 (H5N1) (HPAI
H5N1) was obtained from the repository at the Centers for Disease
Control and Prevention, Atlanta, GA, USA. The A/Chicken/Delaware/
VIVA/04 (H7N2) virus was kindly provided by Dr Dennis Senne,
National Veterinary Services Laboratory, APHIS-USDA, Ames, IA,
USA. The titre of stock viruses was measured by plaque assay on
MDCK cells at 37 or 32 uC or by 50% egg infectious dose (EID50)a s
described previously (Reed & Muench, 1938). All in vitro studies
using HPAI virus were performed in an enhanced Biosafety Level 3
(BSL-3) facility approved by the US Department of Agriculture
(USDA).
Generation of recombinant viruses by reverse genetics. The H7
and N2 genes of the H7N2 virus and DH5 (deletion of polybasic
amino acids) and N1 genes of the HPAI H5N1 virus were cloned as
described by Song et al. (2007). Recombinant viruses were generated
by DNA transfection into co-cultured 293T and MDCK cells as
described previously (Hoffmann et al., 2000). Recombinant virus
stocks were prepared in the allantoic cavity of 10-day-old embryo-
nated chicken eggs. For each virus prepared, RT-PCR and sequencing
were performed for each viral segment to determine their identity.
Sequences were generated using a specific set of primers, a Big Dye
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and a
3100 Genetic Analyzer (Applied Biosystems), according to the
manufacturer’s instructions.
Animal studies. Five-week-old female BALB/c mice (Charles River
Laboratories) were anaesthetized with isofluorane before intranasal
inoculation with 50 ml virus suspension. The 50% mouse lethal dose
(MLD50) for the WSN, A/VN/1203/04 and recombinant viruses was
calculated using groups of four mice inoculated intranasally (i.n.)
with various doses ranging from 10
0 to 10
6 p.f.u. per mouse so that
mice could be challenged in later experiments with 20 MLD50.
Clinical symptoms, body weight and mortality of mice were
monitored and recorded for 14 or 21 days as indicated. Animal
studies using H1N1 recombinant viruses were conducted under BSL-
2 conditions, whereas those with H5N1 (HPAI) recombinants were
performed under BSL-3 conditions with USDA approval. Animal
studies were performed according to protocols approved by the
Animal Care and Use Committee of the University of Maryland.
Evaluation of the protective efficacy of recombinant viruses. To
evaluate the induction of immune responses and the protective capacity
of the recombinant viruses against wild-type WSN virus challenge, mice
(seven per group) were immunized i.n. with recombinant viruses in a
50 ml volume at various doses ranging from 10
3 to 10
6 p.f.u. per mouse.
To evaluate the induction of immune responses and the protective
capacity of the recombinant viruses against wild-type HPAI H5N1 virus
challenge, mice (20 per group) were immunized i.n. with recombinant
viruses in a 50 ml volume at 10
6 EID50 per mouse. All mock-immunized
mice received 50 ml PBS. At 21 days post-inoculation (p.i.), sera were
collected for antibody titration. At 21 days p.i., mice (10 per group)
were challenged with 10
5 p.f.u. (20 MLD50) WSN virus or 20 EID50
(20 MLD50) HPAI H5N1 virus by the intranasal route. Alternatively,
mice (10 per group) received a booster immunization at 21 days post-
vaccination, and 21 days later were challenged as described above. At
3 days post-challenge (p.c.) (and 6 days p.c. where indicated), three
mice per group were sacrificed and their lungs collected and
homogenized to measure virus titres. Lung homogenates were prepared
inPBS and frozen at 270 uC until use. Virus titres in lung homogenates
weredeterminedbyplaqueassay(WSN)orasTCID50(HPAI H5N1) on
MDCK cells at 37 uC.
Microneutralization assays. Sera treated with receptor destroying
enzyme were serially diluted twofold in PBS and placed into 96-well
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of 50 ml containing 100 TCID50 virus diluted in PBS into each well,
the plates were mixed and incubated at 37 uC for 1 h. Subsequently,
the serum/virus mixture (100 ml) was added to a monolayer of
MDCK cells in a 96-well plate. The plate was incubated at 4 uC for
15 min and then transferred to 37 uC for 45 min. After incubation,
the serum/virus mixture was removed and 200 ml Opti-MEM I with
1 mg TPCK-trypsin ml
21 was added. The cells were incubated at
37 uC for 3 days and an HA assay was performed. Neutralizing
antibody titres were expressed as the reciprocal of the highest dilution
of the sample that completely inhibited haemagglutination. HA assays
were performed following the recommendations of WHO/OIE.
RESULTS
In vitro characterization of recombinant viruses
carrying the internal genes of the genetically
modified influenza A/Guinea fowl/Hong Kong/
WF10/99 (H9N2) virus
The ts phenotype of the influenza A/Ann Arbor/6/60
(H2N2) MDV-A strain has been mapped to 3 aa mutations
in PB1 (K391E, E581G and A661T), one in PB2 (N265S)
and one in NP (D34G) (Jin et al., 2004). We showed
previously that the ts loci in the PB2 and PB1 genes of the
MDV-A strain could be transferred to the WF10 virus
backbone producing a similar ts phenotype (Song et al.,
2007) and that the addition of an HA tag at the C terminus
of the PB1 gene provided an attenuated phenotype in
chickens and quail. To characterize further the biological
properties of attenuated viruses using the WF10 backbone
and to determine their potential as universal vaccine
donors, we created additional recombinant viruses and
tested them in vitro. We rescued three recombinant
viruses, called 6WF10:2H1N1, 6WF10ts:2H1N1 and
6WF10att:2H1N1. The 6WF10:2H1N1 virus contains
the internal genes of the WF10 virus and the HA and NA
genes of the influenza A/WSN/33 (H1N1) virus. The
genetic background of the 6WF10ts:2H1N1 virus was the
same as the 6WF10:2H1N1 virus, except that the PB2 and
PB1 genes carried the ca/ts/att MDV-A mutations. The
6WF10att:2H1N1 virus carried the ca/ts/att loci and HA
tag modification.
We analysed the growth characteristics of the recombinant
viruses at different temperatures in MDCK cells. The
recombinant viruses grew as efficiently as the wild-type
virus in eggs incubated at 35 uC, with titres ¢7.0 log10
p.f.u. ml
21 (Table 1). Plaque formation in MDCK cells for
the 6WF10ts:2H1N1 and 6WF10att:2H1N1 viruses was
impaired at 37 uC compared with the 6WF10:2H1N1
virus, which is consistent with the presence of ts mutations
in their respective backbones. The 6WF10att:2H1N1 and
6WF10ts:2H1N1 viruses produced relatively larger plaques
and grew better at 32 uC than at 37 or 38.5 uC (Table 1). As
expected, the 6WF10:2H1N1 virus did not show a
significant reduction in plaque numbers at 37 uC and only
a slight 0.5 log10 reduction at 38.5 uC. In contrast, plaque
formation by the 6WF10ts:2H1N1 virus was reduced by
0.6 log10 at 37 uC and 3.4 log10 at 38.5 uC, respectively,
compared with at 32 uC. The 6WF10att:2H1N1 double-
mutant virus had plaque numbers that were reduced by 1.0
log10 at 37 uC and was unable to produce plaques at
38.5 uC, which is consistent with our previous observa-
tions. These studies suggested that the ts phenotype in our
WF10 backbone would be manifested, regardless of the
surface genes.
Genetically modified WF10att viruses with H1N1
surface genes are attenuated in mice
Mice were inoculated with different doses of the WSN
wild-type, 6WF10:2H1N1, 6WF10ts:2H1N1 or
6WF10att:2H1N1 virus (only doses for 10
5 and 10
6
p.f.u. for the WSN and 10
6 p.f.u. for the mutant viruses
are shown; Table 2). Severe clinical symptoms were
Table 1. Reduction in recombinant virus titres at the indicated
temperatures compared with the permissive temperature
(32 6C)
NP, No plaques detected.
Virus Plaque reduction
(log10 p.f.u. ml
”1)
Stock virus titre
(log10 p.f.u. ml
”1)*
37 6C 38.5 6C
6WF10att:2H1N1 1.0 NP 7.3
6WF10ts:2H1N1 0.6 3.4 7.6
6WF10:2H1N1 20.1 0.5 7.4
WSN 0.3 1.2 7.3
*Viruses were grown for 48 h in the allantoic cavity of 10-day-old
embryonated chicken eggs. The amount of virus in the allantoic fluid
was determined by plaque assay on MDCK cells at 32 uC. Results
represent the mean of two independent experiments.
Table 2. Survival of mice following infection with recombinant
viruses generated by reverse genetics
Virus Infection dose Survival (no. survivors/
no. tested)*
A/WSN/33 (H1N1) 10
6D 0/4
10
5D 0/4
6WF10:2H1N1 10
6D 2/4
6WF10att:2H1N1 10
6D 4/4
A/Vietnam/1203/04
(H5N1)
10
6d 0/4
6WF10:2H5N1 10
6d 0/4
6WF10att:2H5N1 10
6d 2/4
6WF10att:2DH5N1 10
6d 4/4
6WF10att:2H7N2 10
6d 4/4
*Survival of mice was monitored for 14 days p.i.
DTitre in p.f.u.
dTitre in EID50.
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died within 8 days when inoculated with 10
6 or 10
5 p.f.u.
virus (Table 2). Similarly, mice infected with the
6WF10:2H1N1 virus showed severe signs of disease and
half of them (two of four) died when inoculated with 10
6
p.f.u. virus (Table 2). A noticeable reduction in body weight
was also observed when mice were inoculated with 10
5 p.f.u.
6WF10:2H1N1 virus (Fig. 1a). In contrast, mice infected
with the 6WF10ts:2H1N1 or the 6WF10att:2H1N1 virus
exhibited no clinical signs of influenza infection and none of
them died (Fig. 1a). These results indicated that the
6WF10ts:2H1N1 and 6WF10att:2H1N1 viruses are atte-
nuated in mice.
Next, we checked the replication of recombinant viruses in
mouse lungs. As shown in Table 3, the 6WF10ts:2H1N1
virus replicated poorly in mouse lungs. The growth of the
6WF10ts:2H1N1 virus in mouse lungs was approximately
1.4 and 3.8 log10 lower than the 6WF10:2H1N1 or WSN
virus. This difference was greater when mice were
inoculated with a lower dose of virus. Furthermore, the
double-mutant 6WF10att:2H1N1 virus was even more
attenuated in mice than the 6WF10ts:2H1N1 virus
(Table 3). Thus, the growth of the 6WF10att:2H1N1 virus
was highly restricted in mice and this was consistent with
our in vitro plaque-reduction assays.
Attenuation in mice of WF10att viruses in the
context of H5N1 and H7N2 subtypes
The attenuated phenotype of WF10 recombinant viruses
carrying the HA and NA genes of an HPAI H5N1 virus, its
Fig. 1. Attenuation and protective efficacy of the genetically
modified WF10 influenza virus backbone in mice. (a) Mice (four
per group) were infected with the indicated doses (p.f.u.) of
recombinant H1N1 viruses. (b) Mice (four per group) were infected
(10
6 EID50 per mouse) with the indicated recombinant H5N1
viruses carrying an HPAI H5 HA protein. Days on which mice died
are indicated by 3. (c) Mice (four per group) were vaccinated with
the indicated doses (p.f.u.) of the 6WF10att:2H1N1 virus and
21 days later were challenged with 20 MLD50 per mouse of the
WSN H1N1 virus. (d) Mice (four per group) were vaccinated with
10
6 EID50 per mouse of the 6WF10att:2DH5N1 virus and 21 days
later challenged with 20 MLD50 per mouse of the HPAI H5N1 virus.
In all experiments, changes in body weight and clinical signs of
disease were followed over time.
Table 3. Replication of recombinant vaccine viruses in mouse
lungs at 3 days post-infection
Mice were inoculated i.n. with virus at the indicated dose. At 3 days
post-infection, lungs were collected and homogenized for virus
titration. Data are the means of virus titres from four mice in each
group. 2, Not tested; ND, not detected; BLD, below limit of detection.
Virus Infectious virus dose used
10
6 10
5 10
4 10
3
WSN 2 7.1±0.1* 6.8±0.1* 5.5±0.2*
6WF10:2H1N1 2 4.7±0.1* 4.2±0.3* 3.0±0.2*
6WF10ts:2H1N1 2 3.3±0.3* 2.2±0.2* BLD
6WF10att:2H1N1 BLD BLD 22
6WF10att:2DH5N1 BLD 222
6WF10att:2H7N2 2.9±0.8D 222
*Titre in log10 p.f.u. per lung.
DTitre in log10 EID50 per lung.
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H5 HA removed (DH5N1) and H7N2 subtypes was
evaluated in mice (Table 2). Mice inoculated with the
6WF10:2H5N1 strain, which resembles a wild-type HPAI
H5N1 virus, showed severe clinical symptoms (Fig. 1b) and
four of four mice died within 8 days (Fig. 1b). Interestingly,
mice infected with the 6WF10att:2H5N1 virus – carrying
the WF10att virus backbone and the wild-type HPAI H5N1
surface genes – showed a less severe outcome of disease.
Although two of four mice died, the WF10att was noticeably
less virulent than the 6WF10:2H5N1 or the HPAI H5N1
wild-type virus. This observation was further confirmed by
MLD50 assays, which required 10
6 EID50 of the
6WF10att:2H5N1 virus compared with ,10
2 EID50 for
the 6WF10:2H5N1 virus (the exact lower limit was not
tested) or 1 EID50 for the HPAI H5N1 virus (data not
shown). These results highlight the attenuated nature of the
WF10att backbone, even in the context of HPAI H5N1
surface genes. As expected, mice infected with the
6WF10att:2DH5N1 or 6WF10att:2H7N2 virus exhibited
no clinical signs of influenza infection and none of them
died (Table 2). The 6WF10att:2DH5N1 virus was not
detected in the lungs; however, the 6WF10att:2H7N2 virus
was detected in the lungs at 3 days p.i. (Table 3). The
limited, although clearly discernible, replication of the
6WF10att:2H7N2 virus in mouse lungs contrasted with
the absence of the virus in chickens and quail lungs as
described previously (Song et al., 2007). It should be noted
that the 6WF10att:2H7N2 obtained from mouse lungs at
3 days p.i. was not a non-attenuated revertant strain. For
reasons that are beyond the scope of this report, the
6WF10att:2H7N2 virus showed better replication in mouse
lungs than the 6WF10att:2H1N1 or 6WF10att:2DH5N1
virus (Table 3). Nevertheless, these results indicated that the
WF10att backbone is attenuated in mice, whichever surface
proteins are present.
The WF10att backbone provides protection in
mice against homologous challenge with lethal
H1N1 or H5N1 subtype
In order to determine the protective efficacy of the
6WF10att backbone for mice against the WSN virus, we
immunized mice i.n. with 10
4,1 0
5 or 10
6 p.f.u. of the
6WF10att:2H1N1 virus. At 21 days p.i., mice were
challenged with a lethal dose of the virulent WSN virus.
Mice immunized with the 6WF10att:2H1N1 virus sur-
vived the challenge with no signs of disease, although a
significant decrease in body weight was observed in the
group immunized with the lowest vaccine dose (Fig. 1c). In
contrast, the mock-immunized group developed severe
pneumonia, showed drastic body weight loss and even-
tually died by 8 days p.i. (Fig. 1c). More importantly, mice
vaccinated with 10
6 p.f.u. of the 6WF10att:2H1N1 virus
showed a significant reduction in the level of challenge
virus isolated from lungs by 3 days p.i. in contrast to the
mock-vaccinated mice (Table 4). These data suggested that,
at doses that showed either very limited or undetectable
replication in the mouse lung, the 6WF10att:2H1N1 virus
was able to induce immune responses that completely
protected mice from challenge with the lethal WSN virus.
We next evaluated the protection of the recombinant
6WF10att:2DH5N1 against HPAI H5N1 challenge. As
shown in Fig. 1(d), all mice vaccinated with
6WF10att:2DH5N1 were protected against lethal HPAI
H5N1 challenge. A slight body weight loss (about 10%)
was evident between 5 and 8 days p.c. All mice gained body
weight thereafter without overt signs of disease. In contrast,
mock-vaccinated mice died by day 10 (Fig. 1d). Virus
clearance was monitored at days 3 and 6 p.c. As shown in
Table 4, virus titres within the lungs were significant,
although a very slight reduction was observed in mice
vaccinated with 6WF10att:2DH5N1 at 6 days p.c. with a
Table 4. Clearance of challenge virus in mice immunized with recombinant vaccine virus
Immunized with Immunization dose
(p.f.u. or EID50)
per mouse)
Challenged
with 20 MLD50 of:*
Challenge virus titre at
3 days p.c. (log10 p.f.u./
TCID50 per lung)
Challenge virus titre
at 6 days p.c. (log10
TCID50 per lung)
PBSD – WSN 7.3±0.1 2
WSND 10
3 WSN BLD 2
6WF10att:2H1N1D 10
6 WSN BLD 2
6WF10att:2H1N1D 10
5 WSN 2.8±0.9 2
PBSd HPAI H5N1 5.7±0.3 7.1±0.3
6WF10att:2DH5N1d 10
6 HPAI H5N1 5.5±0.4 4.9±0.1
6WF10att:2DH5N1+boosterd 10
6 HPAI H5N1 6.8±0.2 2.3±0.1
6WF10att:2H7N2d 10
6 HPAI H5N1 5.0±0.3 5.1±0.3
6WF10att:2H7N2+booster 10
6 HPAI H5N1 5.8±0.2 5.8±0.8
*Immunized mice were challenged with 10
5 p.f.u. WSN virus or 20 EID50 HPAI H5N1 (equivalent to 20 MLD50). At 3 or 6 days post-
immunization, the lungs were collected and homogenized, and virus titres were assayed by plaque assay or TCID50 determination in MDCK cells.
The data indicate the mean lung virus titre±SD from three mice per group. BLD, Below limit of detection; 2, not tested.
DResults given in p.f.u.
dResults given as TCID50.
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virus was detected in the immunized mice at 3 and 6 days
p.c., despite complete protection against the HPAI H5N1
virus, we wanted to test whether a booster immunization
would result in a better response and faster virus clearance
(Table 4 and Fig. 2c). Our results suggested that booster
immunization improved the overall response to HPAI
H5N1 challenge. No significant body weight loss was
detected in the boosted mice, whilst a substantial reduction
in challenged virus was seen in the booster group at 6 days
p.c.: only 2.3 log10 TCID50 virus was present compared
with single immunization where 4.9 log10 TCID50 virus
was present. These results suggested that the single dose of
the WF10att backbone can protect mice against homolog-
ous virus challenge, but that a booster leads to faster virus
clearance.
The WF10att backbone provides protection in
mice against heterologous challenge
In order to understand whether intranasal immunization
of recombinant viruses induced cross protective immunity
against H1N1 or H5N1 viruses, groups of seven or 10 mice
were immunized with a heterologous subtype,
6WF10att:2H7N2 virus (Song et al., 2007). Mice immu-
nized with a single dose of 6WF10att:2H7N2 survived the
lethal challenge with both the WSN virus and HPAI H5N1
(Fig. 2a, b). Mice immunized with the 6WF10att:2H7N2
virus showed some body weight loss (about 15% between
days 4 and 6), although they all survived the challenge.
These results suggested that the WF10att backbone is
capable of providing cross-protective immunity against
two different lethal virus challenges. Interestingly, signific-
ant virus titres were found at 3 and 6 days p.c. in the lungs
of mice challenged with the HPAI H5N1 virus (Table 4).
We investigated whether improved clearance of the
challenged virus could be achieved following a booster
vaccination regime (Table 4 and Fig. 2c). Mice that
received two doses of the 6WF10att:2H7N2 virus showed
minimal weight loss, displayed no disease signs and were
completely protected from challenge with HPAI H5N1.
However, the single-dose and booster immunization
groups had similar levels of challenge HPAI H5N1 virus
at 3 or 6 days p.c. (Table 4). It should be noted that
heterologous protection was not necessarily due to the
ability of the 6WF10att:2H7N2 virus to replicate in mouse
lungs. Using another WF10att subtype virus, the
6WF10att:2H9N2 virus, which did not replicate in mouse
lungs, we achieved similar levels of cross-protection (data
not shown). These results suggest that protection by the
6WF10att:2H7N2 virus is probably provided by cell-
mediated mechanisms that do not prevent initial replica-
tion of the HPAI H5N1 virus. Thus, the WF10att backbone
provides protection in mice against heterologous challenge
with either WSN or HPAI H5N1 virus, although it does
not prevent virus replication at the early stages of infection.
Significant variations in the ability of recombinant
WF10att viruses to induce neutralizing antibody
responses
To evaluate the immune responses induced by the WF10att
viruses that protected mice against lethal challenge with
WSN and HPAI H5N1, we determined the levels of
neutralizing antibody in the sera of immunized mice using
microneutralization assays. As shown in Table 5, discern-
ible and adequate neutralizing responses were observed in
Fig. 2. Heterologous protection in mice after single-dose and
booster immunization regimes using an attenuated WF10 H7N2
virus. (a) Mice (four per group) were vaccinated with 10
6 EID50 per
mouse of the 6WF10att:2H7N2 virus and challenged 21 days
later with 20 MLD50 per mouse of the WSN H1N1 virus. (b) Mice
(four per group) were vaccinated with 10
6 EID50 per mouse of the
6WF10att:2H7N2 virus and challenged 21 days later with
20 MLD50 per mouse of the HPAI H5N1 virus. (c) Mice (four per
group) were vaccinated with 10
6 EID50 per mouse of the
6WF10att:2H7N2 virus. At 21 days p.i., mice received a second
dose of the 6WF10att:2H7N2 virus, and 21 days after this
booster immunization, mice were challenged with 20 MLD50 per
mouse of the HPAI H5N1 virus. In all experiments, changes in body
weight and clinical signs of disease were followed over time.
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were similar to those obtained using either the
6WF10:2H1N1 or WSN virus (data not shown). Lower
neutralizing antibody titres were observed in the pooled
sera of the four surviving mice immunized with a single
dose of 6WF10att:2H7N2 virus against its homologous
virus; however, after the booster, an increased neutralizing
antibody titre was clearly observed (Table 5). As expected,
the 6WF10att:2H7N2 virus showed no cross-reactive
antibodies that could neutralize the heterologous WSN or
H5N1 virus. Interestingly, mice vaccinated with the
6WF10att:2DH5N1 virus showed no discernible neutral-
izing antibody reaction, even after booster immunization.
These data suggested that survival of mice from challenge is
not solely dependent on neutralizing antibodies; rather,
there may be a combination of humoral and cell-mediated
responses.
DISCUSSION
Recent studies have indicated that transferring the ts amino
acid signature of the MDV-A virus into different human
influenza strains results in a ts phenotype in vitro and
attenuation in ferrets (Jin et al., 2004). Because of the
transferable nature of the ts mutations of the MDV-A virus,
we sought to determine whether such mutations would
impart a similar phenotype to an AIV. For this purpose, we
chose a virus that has demonstrated a broad host range in
order to generate an attenuated virus backbone that could
be used for the development of a universal vaccine for
multiple animal species, i.e. from poultry to humans. We
chose the internal genes of the AIV A/Guinea fowl/Hong
Kong/WF10/99 (H9N2), which replicates and transmits
efficiently in birds, causes respiratory disease in mice
without adaptation and replicates efficiently in ferrets (H.
Wan and others, unpublished data) (Choi et al., 2004). We
successfully generated attenuated H1N1, H5N1 and H7N2
reassortant viruses with the internal genes from the
WF10att virus backbone.
There are obvious limitations in the preparation of
influenza vaccine stocks in the advent of a pandemic that
are inherent to the rapid mutability of the virus. Thus, it is
not possible to predict whether the antigenic make-up of
the vaccine seed stock would confer protective immunity
against the pandemic strain. Meanwhile, the world is
experiencing a pandemic of influenza in birds caused by an
H5N1 virus in which multiple domestic and wild avian
species are involved (Webster et al., 2007). Although this
H5N1 virus has been restricted to Eurasia and some
countries in Africa, there is a latent risk that this virus may
spread worldwide. The H5N1 virus has also shown an
unusually expanded host range, i.e. not only have birds and
humans been infected and died, but feline species,
otherwise regarded as resistant to influenza, have also
experienced a similar fate. In fact, little is known about the
extent of the host range of the H5N1 virus in nature.
Culling and quarantine complemented with the use of
vaccines are being implemented to control the spread of
the H5N1 virus in domestic poultry and to minimize the
risk of human exposure (Capua & Alexander, 2002, 2004;
Capua & Marangon, 2004). Approved vaccines for poultry
rely on inactivated vaccines or a fowlpox recombinant virus
(Capua et al., 2003). Parenteral administration of these
vaccines limits their use in mass vaccination campaigns.
The magnitude of an H5N1 outbreak may be managed or
prevented with vaccination strategies performed by asper-
sion, in ovo or by drinking water, so that thousands of birds
can be immunized at the same time with few labour costs.
A second issue has recently emerged during the preparation
of inactivated vaccines and is related to the human health
risks of personnel exposed to AIVs whose interspecies
potential is poorly defined.
Previously, we showed the WF10att backbone was able to
replicate in the upper respiratory tracts of chickens and no
or very little virus was found in the lungs or cloaca,
suggesting attenuation in chickens (Song et al., 2007). In
this paper, we have shown that incorporation of the ts loci
of MDV-A and an HA tag in the PB1 gene of WF10
Table 5. Microneutralization (MN) antibody titres in mouse sera against homologous and heterologous viruses
Immunized with: Immunization dose MN titres against
homologous virus*
MN titres against WSN MN titres against
H5N1
PBS ,10 ,10 ,10
6WF10att:2H1N1 10
6D 160 160 ,10
6WF10att:2H1N1 10
5D 80 80 ,10
6WF10att:2DH5N1 10
6d ,10 ,10 ,10
6WF10att:2DH5N1+booster 10
6d ,10 ,10 ,10
6WF10att:2H7N2 10
6d 40 ,10 ,10
6WF10att:2H7N2+booster 10
6d 160 ,10 ,10
*Sera were collected at 21 days post-immunization. The data represent pooled sera from four mice per group. MN assays were performed using
homologous viruses: A/WSN/33 (H1N1), A/Vietnam/1203/04 (DH5N1) and A/Chicken/Delaware/VIVA/04 (H7N2).
DTitre in p.f.u.
dTitre in TCID50.
D. Hickman and others
2688 Journal of General Virology 89resulted in a virus that was highly attenuated in mice. Mice
infected with 10
6 p.f.u. 6WF10att:2H1N1 (Fig. 1a, Tables 2
and 3), 10
6 EID50 6WF10att:2DH5N1 (Tables 2 and 3) or
6WF10att:2H7N2 (Tables 2 and 3) showed no clinical
signs of disease, very little virus was detected 3 days p.i. in
mouse lungs and none of the mice died, all indicating that
the WF10att backbone is attenuated in mice, whichever
surface genes are present.
As the recombinant WF10att viruses were attenuated in
mice, we determined the protective efficacy of these
viruses. Mice immunized with a single dose (10
6 p.f.u.)
of 6WF10att:2H1N1 or 6WF10att:2H7N2 survived chal-
lenge with 20 MLD50 of lethal WSN, and the
6WF10att:2H1N1-vaccinated mice were able to clear the
challenge virus from their lungs by 3 days p.c. In the case of
HPAI H5N1 challenge, mice immunized with a single dose
(10
6 EID50) or given a booster 21 days after a single dose of
6WF10att:2DH5N1 or 6WF10att:2H7N2 survived chal-
lenge. Unlike the results with the lethal WSN challenge at 3
and 6 days p.c., virus remained in the lungs p.c. although
the mice were completely protected. These data suggested
that, at doses that showed either very limited or
undetectable replication in the mouse lung, the 6WF10att
recombinant viruses were able to induce immune
responses that completely protected mice from challenge
with the lethal WSN or HPAI H5N1 virus. Using
microneutralization assays, we determined the neutralizing
antibody titres induced by the WF10att viruses that
protected the vaccinated mice against lethal WSN and
HPAI H5N1 challenge. Adequate neutralizing antibodies
were observed in mice immunized with 6WF10att:2H1N1,
but no neutralizing antibodies were observed in mice
immunized with a single dose or booster of
6WF10att:2DH5N1, although mice were completely pro-
tected. These results are consistent with previous observa-
tions where neutralizing antibody titres against the HPAI
H5N1 virus were undetectable even after booster immun-
ization, despite 100% survival in challenge studies (Lu et
al., 2006). Although 6WF10att:2H7N2-immunized mice
generated a lower titre of neutralizing antibodies after the
first dose, there was an increase in neutralizing antibody
titre after the booster dose. We did not observe cross-
reactive neutralizing antibodies to the challenge viruses,
WSN or A/Vietnam/1203/04 (H5N1). Although it remains
unclear how WF10att protects, together these observations
strongly suggest that cell-mediated responses are involved
in protecting mice immunized with WF10att viruses
against lethal challenge with WSN or HPAI H5N1 virus.
For a pandemic, and from a practical point of view, it
would be ideal to prepare vaccine seed stocks that can be
used in multiple animal species. We explored this latter
possibility and generated an attenuated AIV with an
extended host range that could be used for the preparation
of vaccines for either birds or mammals. The use of a
universal backbone obviates the need for the reformulation
of a vaccine specifically designed for use in humans, which
would save valuable time as the vaccine itself could already
be in use for other animal species. A live attenuated AIV
vaccine for poultry would be amenable to mass vaccination
and would negate the limitations associated with recom-
binant approaches in terms of prior exposure to the wild-
type virus. The potential of reassortment of the surface
genes of our vaccine virus with a wild-type virus would
limit its use in domestic birds, although this risk could be
greatly minimized by performing in ovo vaccination, as we
have shown recently (Song et al., 2007). Our approach
should also allow the mass vaccination of wild bird species
in which the H5N1 virus appears to have gone through
cycles of increased virulence, the ecological consequences
of which remain to be seen. Our approach also has the
potential for vaccination of domestic pets, such as cats and
dogs, which have also been involved in recent H5N1
influenza outbreaks (Amonsin et al., 2007; Songserm et al.,
2006a, b). Thus, our strategy provides an alternative
approach for the preparation of vaccines for epidemic
and pandemic influenza.
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